GlassScriptPhysician profile
Douglas Jeffery
NPI 1043296130
$486,418.46
in general payments reported to CMS, 2019-2025
44 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $187K · 2020: $83K · 2021: $107K · 2022: $109K · 2023: $513.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $125.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $114,054.51 | 2020-2022 | |
| Celgene Corporation | $110,994.96 | 2019-2022 | |
| Genentech USA, INC. | $79,144.98 | 2019-2022 | |
| Genzyme Corporation | $77,429.45 | 2019-2022 | |
| Biogen, INC. | $57,673.37 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $19,445.30 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $8,987.50 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $7,368.55 | 2019-2022 | |
| Emd Serono, INC. | $5,440.73 | 2019-2023 | Mavenclad |
| Genentech, INC. | $2,447.95 | 2020-2021 | |
| Tg Therapeutics, INC. | $1,489.77 | 2021-2023 | |
| Sk Life Science, INC. | $193.62 | 2021-2023 | |
| Sanofi-Aventis U.S. LLC | $132.42 | 2019-2021 | |
| Horizon Therapeutics Plc | $107.62 | 2022-2023 | Uplizna |
| Supernus Pharmaceuticals, INC. | $93.25 | 2019-2021 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Jeffery listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.